Menu Back toFaculty

7th DIA Regulatory Communication Training Course in Japan

All prices are exclusive of 10% Japanese consumption tax

Faculty

  • Keisuke  Awa

    Keisuke Awa

    • Deputy Director
    • Ministry of Health, Labour and Welfare (MHLW), Japan

  • Masaharu  Doi

    Masaharu Doi

    • Medical Writer, Associate Director
    • PRA Health Sciences, Japan

  • Katsuhiko  Ichimaru

    Katsuhiko Ichimaru

    • Review Director, Office of New Drug IV
    • Pharmaceuticals and Medical Devices Agency (PMDA), Japan

    Mr. Katsuhiko Ichimaru currently serves as Director for MID-NET Project in Office of Medical Informatics and Epidemiology in Pharmaceuticals and Medical Devices Agency (PMDA). He graduated from Faculty of Pharmaceutical science, the University of Tokushima in 2000. He joined Pharmaceuticals and Medical Devices Evaluation Center of National Institute of Health Science (PMDEC), the predecessor of PMDA, in 2002 and continues his career on drug review in PMDA since April 2004. He was engaged in a review of central or peripheral nervous system drugs, antibacterial drugs and antiviral drugs.

  • Akiko  Ikeda, RPh

    Akiko Ikeda, RPh

    • Associate Director, Regulatory Development Dept., Regulatory Affairs Division,
    • Janssen Pharmaceutical K.K., Japan

    Education Background: Graduated Tokyo University of Pharmacy and Life Sciences / Qualification: Licensed Pharmacist / CURRENT POSITION: Senior Manager of Policy Intelligence Department in Janssen Pharma K.K (Japan), A leader of Regulatory Sub Committee in PhRMA Japan, A member of Contents Committee in DIA Japan / SUMMARY OF PROFESSIONAL EXPERIENCE: 5 years of experiences at regulatory policy and intelligence; About 20 years of experiences at regulatory affair area including development for New drugs (NDA/ PMDA consultation); Started the carrier at Sankyo Co. (Currently Daiichi-Sankyo Co.) in 1986.

  • Toshiko  Ishibashi, PhD, RN

    Toshiko Ishibashi, PhD, RN

    • Associate Director,Oncology Medical Science Department
    • Daiichi Sankyo Co., Ltd., Japan

    Toshiko Ishibashi serves at Ono pharmaceutical company from 2018. She previously served at Abbvie as an Associate Clinical Operations Manager 2016-2018. She has experience as an assistant professor at College of Nursing Art and Science, University of Hyogo. She has 16 years of clinical research experience as a Clinical Research Coordinator at Kumamoto University Hospital and St luke’s International Hospital.

  • Takaaki  Ishine

    Takaaki Ishine

    • Senior Clinical Research Specialist
    • MSD K.K., Japan

  • Yomei  Matsuoka, MSc, RPh

    Yomei Matsuoka, MSc, RPh

    • Vice President, Pharmacoepidemiology and PMS Department
    • Daiichi Sankyo Co., Ltd., Japan

    Mr. Matsuoka is Senior Director of Pharmacovigulance Department at Daiichi Sankyo Co., LTD. He joined Sankyo Co., LTD. in 1991, and has worked for Daiichi Sankyo Co., LTD.since 2007. After engagement in clinical development department and regulatory affairs department for over 20 years, and moved to pharmacovigilancedepartment. Currently, he is in charge of safety planning for the several therapeutic areas such as CV, oncology, CNS, vaccines and contrast agents.

  • Naomi  Misaki, MPharm

    Naomi Misaki, MPharm

    • CRC, Research Management
    • St. Luke's International Hospital, Japan

    Ms. Misaki is a manager of a research management at St.Luke's Inernational Hospital. In this position, Ms. Misaki is responsible for managing all clinical trials, IRB and research committees in the hospital. Ms. Misaki also supports research planning in the hospital. Ms. Misaki has 20 years' of experience as a CRC and as a secretary member of the IRB and Research Ethics Review Board.

  • Hiroyuki  Murakami

    Hiroyuki Murakami

    • Duputy Review Director, Office of New Drug I
    • Pharmaceuticals and Medical Devices Agency (PMDA), Japan

    Hiroyuki Murakami is currently deputy review director, Office of New Drug I, PMDA. He is engaged in a review of drugs for metabolic disorders including daibetes mellitus, inborn errors of metabolism, etc. He joined PMDA in 2006, and he served as a reviewer of gastrointestinal disease and kidney disease drugs for about 7 years. From 2013, he had been working as a risk manager of onclogy drugs in Office of Safety II. In 2017, he moved to current position.

  • Norikazu  Takahata

    Norikazu Takahata

    • President
    • Plus Action for Children, Japan

  • Satoshi  Takeuchi

    Satoshi Takeuchi

    • Manager, R&D Regulatory 3, Regulatory Affairs
    • Sanofi.K.K., Japan

  • Nao  Tsuchida, MD, PhD

    Nao Tsuchida, MD, PhD

    • Chief
    • National Hospital Organization Headquarters, Japan

Contact us

Please contact the DIA Japan office in Tokyo for further information.

Tel: +81-3-6214-0574
Fax: +81-3-3278-1313
Japan@DIAglobal.org
www.diajapan.org